Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.00
ALQA's Cash to Debt is ranked lower than
63% of the 778 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.15 vs. ALQA: 1.00 )
Ranked among companies with meaningful Cash to Debt only.
ALQA' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: No Debt Max: No Debt
Current: 1
Equity to Asset 0.71
ALQA's Equity to Asset is ranked higher than
64% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. ALQA: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
ALQA' s Equity to Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.83 Max: 0.99
Current: 0.71
0.57
0.99
F-Score: 3
Z-Score: -1.31
M-Score: -1.56
WACC vs ROIC
16.69%
-42.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -96.47
ALQA's Operating margin (%) is ranked lower than
88% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.44 vs. ALQA: -96.47 )
Ranked among companies with meaningful Operating margin (%) only.
ALQA' s Operating margin (%) Range Over the Past 10 Years
Min: -1119.69  Med: -398.45 Max: -51.07
Current: -96.47
-1119.69
-51.07
Net-margin (%) -73.41
ALQA's Net-margin (%) is ranked lower than
87% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. ALQA: -73.41 )
Ranked among companies with meaningful Net-margin (%) only.
ALQA' s Net-margin (%) Range Over the Past 10 Years
Min: -1222.3  Med: -399.1 Max: -52.73
Current: -73.41
-1222.3
-52.73
ROE (%) -25.50
ALQA's ROE (%) is ranked lower than
81% of the 753 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.76 vs. ALQA: -25.50 )
Ranked among companies with meaningful ROE (%) only.
ALQA' s ROE (%) Range Over the Past 10 Years
Min: -312.57  Med: -70.75 Max: -16.22
Current: -25.5
-312.57
-16.22
ROA (%) -15.60
ALQA's ROA (%) is ranked lower than
80% of the 783 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. ALQA: -15.60 )
Ranked among companies with meaningful ROA (%) only.
ALQA' s ROA (%) Range Over the Past 10 Years
Min: -2368.45  Med: -89.26 Max: -15.45
Current: -15.6
-2368.45
-15.45
ROC (Joel Greenblatt) (%) -544.56
ALQA's ROC (Joel Greenblatt) (%) is ranked lower than
89% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.07 vs. ALQA: -544.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALQA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -53854.55  Med: -1397.71 Max: -55.94
Current: -544.56
-53854.55
-55.94
Revenue Growth (3Y)(%) 41.90
ALQA's Revenue Growth (3Y)(%) is ranked higher than
93% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. ALQA: 41.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALQA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 41.9
Current: 41.9
0
41.9
EBITDA Growth (3Y)(%) 8.60
ALQA's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 564 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.30 vs. ALQA: 8.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALQA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.6  Med: 26.45 Max: 107
Current: 8.6
-67.6
107
EPS Growth (3Y)(%) 7.50
ALQA's EPS Growth (3Y)(%) is ranked higher than
52% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. ALQA: 7.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALQA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.4  Med: 29.9 Max: 116.7
Current: 7.5
-46.4
116.7
» ALQA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ALQA Guru Trades in Q3 2015

Jim Simons 15,900 sh (New)
» More
Q4 2015

ALQA Guru Trades in Q4 2015

Jim Simons 20,000 sh (+25.79%)
» More
Q1 2016

ALQA Guru Trades in Q1 2016

Jim Simons 137,800 sh (+589.00%)
» More
Q2 2016

ALQA Guru Trades in Q2 2016

Jim Simons 271,500 sh (+97.02%)
» More
» Details

Insider Trades

Latest Guru Trades with ALQA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NAS:IMNP, OTCPK:SUWN, OTCPK:INNV, NAS:TNXP, OTCPK:CHEXF, NAS:PRPH, NAS:NVGN, AMEX:CPHI, OTCPK:ECTE, NAS:BSPM, AMEX:AXN, OTCPK:INBP, OTCPK:ENZB, OTCPK:ADIA, OTCPK:CKDXY, OTCPK:PXSLY, NAS:ALIM, OTCPK:FAMDF, OTCPK:BIOYF, AMEX:NNVC » details
Traded in other countries:HL1A.Germany,
Alliqua BioMedical Inc is a biomedical company providing wound care solutions. It is also engaged in contract manufacturing.

Alliqua BioMedical Inc a Florida corporation formed on October 21, 1997. It is a biomedical company through its subsidiary providing advanced wound care solutions. The Company's core business includes; advanced wound care and contract manufacturing. The Company develops, manufactures and markets high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its subsidiary manufactures and markets its hydrogel products. Its products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable it to produce gels that can satisfy rigid tolerance specifications with respect to a range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate (a measure of the passage of water vapor through a substance) and release rate) while maintaining product integrity. In July 2012, it began to market two proprietary products, SilverSeal, a hydrogel wound dressing with silver coated fibers, and Hydress, an over-the-counter hydrogel wound dressing. It supplies these gels mainly to the wound care segment of the healthcare industry. The Company's SilverSeal and Hydress dressings are each currently available in two sizes and are used to provide and maintain a moist wound environment. SilverSeal dressings also provide an antimicrobial barrier. On November 14, 2013 Company entered into a license, marketing and development agreement with Anthrogenesis Corporation, Celgene Cellular Therapeutics ("CCT"), an affiliate of Celgene Corporation, pursuant to which CCT granted an exclusive, royalty-bearing license in its intellectual property related to certain placental based products, including the wound care products Extracellular Matrix ("ECM"), a suite of advanced wound management products made from extracellular matrix derived from the human placenta and Biovance, a collagen-based decellularized and dehydrated topical wound covering produced from human amniotic membrane for the management of non-infected partial- and full-thickness wounds; and also into a supply agreement with CCT, pursuant to which CCT will supply Company with the entire requirement of Biovance for distribution and sale in the United States. The Company's medical devices are subject to the U.S. Food and Drug Administration's general controls, which include compliance with the applicable portions of the U.S. Food and Drug Administration's Quality System Regulation, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. It is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the U

Ratios

vs
industry
vs
history
P/B 0.42
ALQA's P/B is ranked higher than
96% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.08 vs. ALQA: 0.42 )
Ranked among companies with meaningful P/B only.
ALQA' s P/B Range Over the Past 10 Years
Min: 0.39  Med: 1.68 Max: 23.18
Current: 0.42
0.39
23.18
P/S 1.05
ALQA's P/S is ranked higher than
81% of the 695 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. ALQA: 1.05 )
Ranked among companies with meaningful P/S only.
ALQA' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 10.78 Max: 38.71
Current: 1.05
1.02
38.71
Current Ratio 2.73
ALQA's Current Ratio is ranked higher than
54% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. ALQA: 2.73 )
Ranked among companies with meaningful Current Ratio only.
ALQA' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.37 Max: 96.93
Current: 2.73
0.04
96.93
Quick Ratio 2.37
ALQA's Quick Ratio is ranked higher than
60% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. ALQA: 2.37 )
Ranked among companies with meaningful Quick Ratio only.
ALQA' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2 Max: 96.93
Current: 2.37
0.04
96.93
Days Inventory 172.05
ALQA's Days Inventory is ranked lower than
74% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.00 vs. ALQA: 172.05 )
Ranked among companies with meaningful Days Inventory only.
ALQA' s Days Inventory Range Over the Past 10 Years
Min: 11.87  Med: 54.54 Max: 172.05
Current: 172.05
11.87
172.05
Days Sales Outstanding 48.55
ALQA's Days Sales Outstanding is ranked higher than
74% of the 579 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.08 vs. ALQA: 48.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALQA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.55  Med: 34.04 Max: 73.9
Current: 48.55
13.55
73.9
Days Payable 112.89
ALQA's Days Payable is ranked higher than
75% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 67.81 vs. ALQA: 112.89 )
Ranked among companies with meaningful Days Payable only.
ALQA' s Days Payable Range Over the Past 10 Years
Min: 24.61  Med: 113.85 Max: 196.17
Current: 112.89
24.61
196.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -67.20
ALQA's 3-Year Average Share Buyback Ratio is ranked lower than
95% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. ALQA: -67.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALQA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.2  Med: -14.5 Max: 30.3
Current: -67.2
-67.2
30.3

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 37.00
ALQA's Price/Net Current Asset Value is ranked lower than
92% of the 441 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.54 vs. ALQA: 37.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALQA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.78  Med: 16.78 Max: 3325
Current: 37
4.78
3325
Price/Tangible Book 7.40
ALQA's Price/Tangible Book is ranked lower than
77% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. ALQA: 7.40 )
Ranked among companies with meaningful Price/Tangible Book only.
ALQA' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.35  Med: 9.15 Max: 2406
Current: 7.4
4.35
2406
Price/Median PS Value 0.10
ALQA's Price/Median PS Value is ranked higher than
99% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. ALQA: 0.10 )
Ranked among companies with meaningful Price/Median PS Value only.
ALQA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.1  Med: 0.93 Max: 3.05
Current: 0.1
0.1
3.05
Earnings Yield (Greenblatt) (%) -67.48
ALQA's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. ALQA: -67.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALQA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -421.86  Med: 0 Max: 0
Current: -67.48
-421.86
0

More Statistics

Revenue (TTM) (Mil) $18.90
EPS (TTM) $ -0.49
Beta1.72
Short Percentage of Float1.29%
52-Week Range $0.70 - 3.88
Shares Outstanding (Mil)29.67

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 19 22 29 37
EPS ($) -0.56 -0.83 -0.71 -0.53
EPS w/o NRI ($) -0.56 -0.83 -0.71 -0.53
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ALQA

Headlines

Articles On GuruFocus.com
CFO of Alliqua BioMedical Inc Buys 2,500 Shares Aug 12 2015 
Market Overlooks Alliqua’s First MAC Coverage Apr 21 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
Alliqua BioMedical, Inc. Expands Regenerative Medicine Portfolio with the Commercial Introduction of... Sep 19 2016
Alliqua BioMedical, Inc. Expands Regenerative Medicine Portfolio with the Commercial Introduction of... Sep 19 2016
ETF’s with exposure to Alliqua BioMedical, Inc. : August 24, 2016 Aug 24 2016
ALLIQUA BIOMEDICAL, INC. Financials Aug 17 2016
ETF’s with exposure to Alliqua BioMedical, Inc. : August 12, 2016 Aug 12 2016
Alliqua BioMedical, Inc. :ALQA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 Aug 11 2016
Edited Transcript of ALQA earnings conference call or presentation 9-Aug-16 12:00pm GMT Aug 09 2016
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 09 2016
Alliqua beats 2Q profit forecasts Aug 09 2016
Alliqua beats 2Q profit forecasts Aug 09 2016
Alliqua BioMedical, Inc. Reports Second Quarter and Six Months Fiscal Year 2016 Financial Results Aug 09 2016
Q2 2016 Alliqua BioMedical Inc Earnings Release - Before Market Open Aug 09 2016
Alliqua BioMedical, Inc. Reports Second Quarter and Six Months Fiscal Year 2016 Financial Results Aug 09 2016
Will Q2 Earnings Hold a Surprise for Davita (DVA) Stock? Aug 05 2016
Humana (HUM) May Beat Q2 Earnings: Will the Stock Gain? Aug 02 2016
These 5 Stocks Are Primed for Breakouts Jul 15 2016
Edited Transcript of ALQA earnings conference call or presentation 10-May-16 12:00pm GMT Jul 14 2016
Edited Transcript of ALQA earnings conference call or presentation 23-Feb-16 1:00pm GMT Jul 14 2016
Alliqua BioMedical And BSN medical Reach Distribution Rights Agreement For Sorbion Dressing Products Jul 07 2016
Alliqua BioMedical, Inc. and BSN medical, Inc. Announce Definitive Agreement on Distribution Rights... Jul 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)